Kate Gifford 
You may have left the concept of a ‘model eye’ back in your student days – learn how understanding the ocular power components of the eye can be applied to clinical diagnosis and management decisions in childhood progressive myopia.
Optimizing safety in orthokeratology is crucial for successful patient outcomes. Learn about compliance challenges in children wearing ortho-k and how to manage them, as well as the latest data on safety and rates of complications as reported from clinical studies.
This is the first meta-analysis to directly compare mean axial growth across studies, looking at how age and ethnicity contribute to differences. Current axial length growth charts differentiate by sex and ethnicity, with age being the key variable. The results indicate that mean annual axial length growth is 28% greater in Asian compared to non-Asian children., reaffirming the need for Asian-specific data.
Comparison of myopia control interventions shows that around half of the total efficacy is observed in the first 12 months. How can we use this knowledge to select and monitor the most suitable treatment for the individual child with myopia? Learn more here.
Atropine 0.01% combined with orthokeratology slows axial elongation to less than 0.1mm/year over two years in Chinese children aged 6-11 years. This is the equal-longest study on this topic and first to measure potential mechanisms of pupil size and choroidal thickness. The largest effect of the combination occurred in the first 6 months.
The International Myopia Institute released their Volume 1 of reports in 2019 and Volume 2 in 2021. Here, we explore the latest round of reports in 2021 and what they each mean for clinical practice.
If your patient is a unilateral myope, sometimes the myopic eye is the easier one to manage! This case study explores the options to appropriately diagnose, track and manage the non-myopic eye in a unilateral myope – where the non-myopic eye seems to be progressing faster than the myopic eye treated with orthokeratology.
What does on-label and off-label prescribing mean in myopia management? Here we explore this topic from the point of view of medications and medical devices, what regulatory approvals mean and how this applies to decision making and clinical processes such as informed consent.
This new systematic review and meta-analysis has evaluated use of smartphones and tablets separately to computer use and other non-screen based near work. Results are still mixed but overall there was a trend for a slightly increased risk with mobile device use alone, which increased when combined with computer use. More objective measures of screen time are needed to further explore this link.
This study reports two year results from a randomized clinical trial examining myopia control spectacle lenses with highly aspherical lenslets (HAL) or slightly aspherical lenslets (SAL). The findings showed the HAL lens controlled refractive and axial progression by 50-55% and SAL by around 30% over two years. Read more about the outcomes and comparisons to other myopia control spectacles here.
